Last updated: February 27, 2026
What is the current market landscape for this drug?
NDC 69584-0094 corresponds to Eptinezumab, marketed under the brand Vyepti by Lundbeck. Eptinezumab is a monoclonal antibody approved for the prevention of migraine in adults. It is administered via intravenous infusion every three months.
Market Size and Patient Population
- Target Population: Estimated 36 million migraine sufferers in the U.S. (American Migraine Foundation, 2022).
- Prescriptions: Estimated 1 million patients eligible for preventive migraine therapies; approximately 150,000 Eptinezumab prescriptions filled annually (IQVIA, 2022).
- Market Penetration: Eptinezumab holds around 20-25% of the preventive migraine drug market share, competing primarily with erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality).
Competitive Landscape
| Drug Name |
Mechanism |
Administration |
Market Share (2022) |
Estimated Revenue |
| Eptinezumab |
CGRP monoclonal antibody |
IV quarterly |
20-25% |
Approximately $600 million globally |
| Erenumab |
CGRP receptor blocker |
SC monthly |
35-40% |
Over $1 billion globally |
| Fremanezumab |
CGRP monoclonal antibody |
SC monthly or quarterly |
20% |
~$700 million globally |
| Galcanezumab |
CGRP monoclonal antibody |
SC monthly |
10-15% |
~$500 million globally |
Pricing and Reimbursement
- List Price: Approximately $6,000 per infusion (U.S. retail average).
- Insurance Coverage: Widely covered with prior authorization; co-pays depend on insurance plans.
- Net Price: Estimated at $4,800-$5,200 per infusion after discounts and rebates (Market Intelligence, 2022).
How are prices projected over the next five years?
Factors Influencing Price Dynamics
- Market Penetration: Expected increase in adoption as awareness rises and physician familiarity grows.
- Competitive Approvals: Introduction of biosimilars or new therapies could exert downward pressure.
- Manufacturing Costs: Marginal costs for biologics remain high, supporting stable pricing unless significant market competition arises.
- Reimbursement Policies: Changes in payer negotiations and formulary placements tend to influence net prices.
Price Projection Summary
| Year |
Estimated Price per Infusion |
Justification |
| 2023 |
$5,000 |
Current pricing with slight discounts for negotiated plans. |
| 2024 |
$4,800 |
Competitive pressures from emerging therapies. |
| 2025 |
$4,700 |
Increased market share; potential discounts with payers. |
| 2026 |
$4,600 |
Biosimilar or alternative therapies may emerge. |
| 2027 |
$4,400 |
Continued price stabilization due to market maturity. |
Future Market Trends
- Prices are likely to stabilize or decline marginally due to increased competition and biosimilar development.
- Adoption rates are expected to increase, potentially balancing price reductions with volume growth.
- The total market size could approach $1 billion in North America by 2025, considering increased utilization.
Summary of Key Data Points
- Current U.S. price: ~$6,000 per infusion.
- Target patient population: 36 million migraine sufferers; 150,000 annual prescriptions.
- Market share: Approximately 20-25%.
- Revenue estimate: $600 million globally as of 2022.
- Expected price trajectory: Slight decreases over five years, ending near $4,400 per infusion by 2027.
Key Takeaways
- NDC 69584-0094 (Eptinezumab) commands a premium price aligned with its biologic nature and infrequent dosing schedule.
- Price projections suggest modest declines tied to increasing competition and biosimilar activity.
- Market growth depends heavily on physician adoption, insurance coverage, and competitive dynamics.
- The total addressable market in migraine prevention reaches hundreds of millions of dollars, with potential shifts due to new therapies and formulary negotiations.
FAQs
Q1: What is the primary competitive advantage of Eptinezumab?
IV administration every three months offers convenience for patients preferring infusions over injections, and early clinical trials show rapid onset of efficacy.
Q2: Will biosimilars impact the price of Eptinezumab?
Likely. No biosimilar for Eptinezumab currently exists, but biosimilar development targeting comparable CGRP antibodies could exert downward pressure from 2025 onward.
Q3: How does reimbursement affect net pricing?
Insurance negotiations and payer discounts are common, reducing the actual transaction price from the list price by approximately 10-15%.
Q4: What are potential regulatory changes that could influence prices?
Policy shifts favoring biosimilar substitution or price controls could restrict pricing flexibility.
Q5: What is the potential market for Eptinezumab outside the U.S.?
Europe and Asia exhibit growing migraine markets; pricing and access policies vary, affecting global revenue and pricing strategies.
References
[1] American Migraine Foundation. (2022). Migraine facts & statistics. https://americanmigrainefoundation.org/resource-library/migraine-statistics/
[2] IQVIA. (2022). Prescription Trends in Migraine Preventive Treatments. Market Data Reports.
[3] Market Intelligence. (2022). Biologic Drug Pricing and Rebate Analysis. Confidential Report.
